Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 19;184(1):29.
doi: 10.1007/s00431-024-05848-1.

Pediatric MASLD: current understanding and practical approach

Anne-Sophie R Stroes  1 , Miriam Vos  2 , Marc A Benninga  1 , Bart G P Koot  3
Affiliations
Review

Pediatric MASLD: current understanding and practical approach

Anne-Sophie R Stroes et al. Eur J Pediatr. .

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most prevalent chronic liver disease in children in industrialized countries mainly due to the rise in obesity and overweight. Besides risk of progressive liver damage, MASLD also carries an increased risk of extra-hepatic morbidity, most importantly type 2 diabetes mellitus and cardiovascular disease. Important challenges remain in the prevention, detection, and treatment of this prevalent disorder. This review outlines the epidemiology and risk factors of MASLD and provides an approach to screening, diagnosis, and treatment based on current best available evidence and expert opinion. What is known: • NAFLD/MASLD is a common disorder in children strongly related to obesity/overweight and insulin resistance. • This silent disorder is underdiagnosed due to lack of awareness and lack of simple diagnostic criteria. What is new: • New diagnostic criteria have transformed NAFLD/MASLD from a diagnosis of exclusion to a positive diagnosis with simple criteria. • Effective treatments are emerging for adults and will likely become available for children. • Identifying children with NAFLD/MASLD has become even more important due to this new treatment perspective.

Keywords: Children; MASH; MASLD; Obesity.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing interests The authors declare no competing interests.

References

    1. Kiess W, Penke M, Sergeyev E, Neef M, Adler M, Gausche R, Korner A (2015) Childhood obesity at the crossroads. J Pediatr Endocrinol Metab. 28(5–6):481–4 - PubMed
    1. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF et al (2020) Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 5(2):167–228 - PubMed
    1. Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U et al (2012) Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 54(5):700–13 - PubMed
    1. Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P et al (2021) Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 6(10):864–73 - PubMed
    1. Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z et al (2021) From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 73(3):1194–8 - PubMed

MeSH terms

LinkOut - more resources